E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067585 |
E.1.2 | Term | Type 2 diabetes mellitus |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067585 |
E.1.2 | Term | Type 2 diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with pioglitazone in patients with type 2 diabetes mellitus with insufficient glycaemic control. |
|
E.2.2 | Secondary objectives of the trial |
• Occurrence of a treat to target response, that is an HbA1c under treatment of < 7.0% after 24 weeks of treatment • Occurrence of a treat to target response, that is an HbA1c under treatment of < 6.5% after 24 weeks of treatment • Occurrence of a relative efficacy response (HbA1c lowering by at least 0.5% after 24 weeks of treatment) • HbA1c reduction from baseline by visit over time • Change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment •Change from baseline in FPG by visit over time
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Diagnosis of type 2 diabetes mellitus prior to informed consent 2. Male and female patients pre-treated with metformin and pioglitazone; antidiabetic therapy has to be unchanged for 12 weeks prior to informed consent. 3. Metformin therapy should be >= 1500 mg/day or on the maximum tolerated dose for 12 weeks prior to informed consent*. 4. Pioglitazone therapy should be 45 mg/day or the maximum clinically acceptable dose in the investigators opinion. The dose should be unchanged for 12 weeks prior to informed consent. 5. Glycosylated haemoglobin A1 (HbA1c) ≥7.5% and ≤ 10 at Visit 1 (randomisation criterion) 4. Age >= 18 and < 80 years at Visit 1 (Screening) 5. BMI <= 45 kg/m2 (Body Mass Index) at Visit 1 (Screening) 6. Signed and dated written informed consent by date of Visit 1a in accordance with GCP and local legislation *Patients currently treated with a total daily dose of less than 1500 mg metformin can be included in the trial if the Investigator has documented that the dose is the maximum tolerated dose of metformin for that patient.
|
|
E.4 | Principal exclusion criteria |
1. Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast or > 400 mg/dl (22.2 mmol/l) in a randomly performed measurement during placebo run-in and confirmed by a second measurement (not on the same day). 2. Myocardial infarction, stroke or TIA within 3 months prior to informed consent 3. Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1 4. Gastric bypass surgery 5. Known hypersensitivity or allergy to the investigational product or its excipients, to metformin or pioglitazone. 6. Metformin and/or pioglitazone are not used in accordance with the local prescribing information. 7. Treatment with rosiglitazone, GLP-1 analogues, DPP-4 inhibitors or insulin within 3 months prior to informed consent 8. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) 3 months prior to informed consent 9. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation as well as drug abuse 10. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent. 11. Participation in another trial with an investigational drug (other than oral antidiabetic treatments) within 2 months prior to informed consent 12. Pre-menopausal women (last menstruation <= 1 year prior to informed consent) who: • are nursing or pregnant or • are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint in this study is the change from baseline in HbA1c after 24 weeks of treatment. Throughout the study protocol, the term "baseline" refers to the last observation prior to the treatment phase. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 13 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
For all patients completing the study according to protocol a follow up contact (Visit 8) with the patient (preferably by phone) should be done by the investigator at the end of the post treatment observation period of 7 days. In case of premature discontinuation from the 24 week treatment period however, a Visit 7 should be performed and the patient should return to a Visit 8, 7 days following Visit 7. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |